[Form 4/A] Clene Inc. Amended Insider Trading Activity

Rhea-AI Filing Summary

Clene Inc. reporting person Mark Mortenson (Chief Science Officer) filed an amended Form 4 correcting an earlier filing to show an option grant for 40,000 shares of common stock. The option was granted 09/25/2025 under the Clene Inc. Amended 2020 Stock Plan with a corrected exercise price of $5.88 per share. The options vest in 12 equal monthly installments beginning 10/25/2025 and expire 09/24/2035. The amendment clarifies the exercise price only; no other transactions or changes in beneficial ownership are reported.

Positive

• 40,000 stock options granted to Chief Science Officer, providing alignment of executive compensation with shareholder interests
• Vesting begins 10/25/2025 and occurs in 12 equal monthly installments, creating a short-term retention incentive

Negative

• None.

Insights

Securities Analyst

TL;DR: Officer received a standard stock option award of 40,000 shares at $5.88, amended to correct the exercise price.

This Form 4/A documents a routine equity compensation grant to a named executive officer rather than a market transaction. The award size (40,000 options) and a 10-year term with monthly vesting over 12 months suggest a near-term retention incentive. The amendment fixes the exercise price to $5.88, which is a clerical correction; no cash proceeds or dispositions are reported. For investors, this is a disclosure of insider compensation rather than a signal of immediate insider buying or selling.

Corporate Governance Expert

TL;DR: Amendment corrects exercise price; vesting schedule is short-term monthly over one year, typical for retention awards.

The filing confirms the grant was made under the companys Amended 2020 Stock Plan and specifies a clear vesting schedule beginning October 25, 2025. The document is compliant in form: it amends a prior Form 4 to correct the exercise price and includes signature by POA. There are no indications of irregular governance actions or material changes to ownership beyond the grant disclosed.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Mortenson Mark

(Last) (First) (Middle)

6550 SOUTH MILLROCK DRIVE

SUITE G50

(Street)

SALT LAKE CITY UT 84121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Clene Inc. [ CLNN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Science Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)
09/29/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
stock option	$5.88(1)	09/25/2025		A		40,000		(2)	09/24/2035	common stock	40,000	$0	40,000	D

Explanation of Responses:

1. This Form 4 amendment is being filed to correct a Form 4 filed on September 29, 2025. The corrected exercise price is $5.88 per share.

2. This option was granted on September 25, 2025 as an option for 40,000 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $5.88 per share. The options vest in 12 equal monthly installments on the 25th day of each calendar month, beginning October 25, 2025, until such shares are fully vested.

	/s/ Jerome T. Miraglia POA	09/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Form 4/A for Clene Inc. (CLNN) disclose?

The amendment discloses a grant of 40,000 stock options to Mark Mortenson with a corrected exercise price of $5.88 per share.

When were the options granted and when do they vest?

The options were granted on 09/25/2025 and vest in 12 equal monthly installments beginning 10/25/2025.

What is the exercise price and expiration date of the options?

The corrected exercise price is $5.88 per share and the options expire on 09/24/2035.

Why was an amended Form 4 filed?

The filer states the amendment was submitted to correct the previously reported exercise price to $5.88.

Does the filing report any sale or purchase of underlying shares?

No. The report shows an option grant (acquisition) and lists 40,000 underlying shares beneficially owned following the transaction; no dispositions are reported.